Astrotech Corporation (ASTC) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Astrotech Corporation (NASDAQ: ASTC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $4.84 (-7.81% 1D, market cap $10.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ASTC ranks #873 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), ASTC carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of 47.5%, and ROIC of -35.0%. By comparison, BNGO (Bionano Genomics Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $16.1M) and EYPT (EyePoint Inc.) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $30.0M). Among the 5-stock peer group, ASTC leads on earnings multiple (N/A) while PRPO leads on capital efficiency (-7.9% ROIC).
Per ASTC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001001907), Astrotech Corporation generated $1.0M in revenue (-41.2% YoY), -$13.8M in net income, and -$13.8M in free cash flow against $19.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
FRED Regime × Technicals: 4% of 52W Range • RSI-14 at 35 (NEUTRAL RANGE)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While ASTC currently carries a cautious 28/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.40) and Max Pain ($5.08) forces dealer call-delta covering toward $72.29.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Astrotech Corporation (ASTC) dropped -7.81% to $4.84, trading at 4% of its 52-week range ($1.92 – $68.85). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Astrotech Corporation (ASTC) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Astrotech Corporation (ASTC) market action, institutional positioning, and fundamental catalysts.
Investing.com Nigeria report covering Astrotech Corporation (ASTC) market action, institutional positioning, and fundamental catalysts.
Stock Traders Daily report covering Astrotech Corporation (ASTC) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Astrotech Corporation (ASTC) market action, institutional positioning, and fundamental catalysts.
The Manila Times report covering Astrotech Corporation (ASTC) market action, institutional positioning, and fundamental catalysts.
The proposed project, Astrotech Vertical Solar Array Maturation (AVSAM), would advance critical elements of the Astrotech Mobile Power System (AMPS) for potential future lunar surface use.The proposal targets maturation
Gainers Republic Power Group (NASDAQ:RPGL) stock moved upwards by 55.5% to $24.09 during Thursday's regular session. The company's market cap stands at $44.9 million. Alpha Modus Holdings (NASDAQ:AMOD) shares
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -41.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ASTC today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ASTC. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Astrotech Corporation (ASTC) ranks #873 by composite RQD confidence (28/100, grade E) and #890 by equity capitalization ($10.2M). Within this direct 5-issuer industry benchmark cohort, ASTC leads on earnings valuation at N/A trailing P/E, while PRPO leads on capital efficiency and profitability with -7.9% ROIC and 44.2% gross margin. RPID currently holds the highest overall quantitative score in the immediate peer group at 34/100 (E) compared with ASTC at 28/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ASTC
ACTIVE
Astrotech Corporation | E | 28/100 | — | 47.5% | -35.0% | -7.81% | $10.2M | Benchmark Subject |
| BNGO Bionano Genomics Inc. | E | 29/100 | — | 46.3% | -35.0% | -4.17% | $16.1M | /bngo-vs-astc → |
| EYPT EyePoint Inc. | E | 26/100 | — | — | -35.0% | -8.32% | $30.0M | /eypt-vs-astc → |
| PRPO Precipio Inc. | E | 30/100 | — | 44.2% | -7.9% | -6.46% | $32.4M | /prpo-vs-astc → |
| RPID Rapid Micro Biosystems Inc. (Class A) | E | 34/100 | — | — | -35.0% | -6.73% | $36.9M | /rpid-vs-astc → |
In its most recent audited fiscal period (FY2025, filed 2025-06-30), Astrotech Corporation (ASTC) reported GAAP revenue of $1.0M (-41.2% vs. FY2024 revenue of $1.7M , and +33.3% cumulative change since FY2023) , GAAP net income of -$13.8M, operating cash flow of -$13.0M, and free cash flow of -$13.8M (-33.8% YoY). On the balance sheet, ASTC closed FY2025 with $19.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-06-30 | $1.0M | -$13.8M | -$13.0M | -$13.8M | $19.7M | — |
| FY2024 (FY) | 2024-06-30 | $1.7M | -$11.7M | -$9.7M | -$10.3M | $31.0M | — |
| FY2023 (FY) | 2023-06-30 | $750.0K | -$9.6M | -$7.6M | -$7.6M | — | — |
As of 2026-11-03, Astrotech Corporation (NASDAQ: ASTC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $4.84 (-7.81% 1D, market cap $10.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ASTC ranks #873 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), ASTC carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of 47.5%, and ROIC of -35.0%. By comparison, BNGO (Bionano Genomics Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $16.1M) and EYPT (EyePoint Inc.) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $30.0M). Among the 5-stock peer group, ASTC leads on earnings multiple (N/A) while PRPO leads on capital efficiency (-7.9% ROIC).
Per ASTC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001001907), Astrotech Corporation generated $1.0M in revenue (-41.2% YoY), -$13.8M in net income, and -$13.8M in free cash flow against $19.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ASTC last traded at $4.84 (-7.81% on volume of 17,874 shares), positioning the stock -24.38% below its 50-day simple moving average ($6.40) and -32.96% below its 200-day simple moving average ($7.22). Across its 52-week range of $1.92 to $68.85, ASTC sits at the 4.4% percentile with a 14-day RSI of 35.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.24 to $5.44).
Why ASTC Stock dropped -7.81% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, ASTC carries an RQD Score of 28 out of 100, a letter grade of E, and a verdict label of "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars score as follows: Fundamental Cash Engine 6/20 (ROIC -35%; FCF yield 0%), Whale 13F Flow 3/20 (institutional accumulation and options positioning), Insider Conviction 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 8/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet 8/20 (Altman Z 2.5; Piotroski F 3/9; Debt/Equity 0.5).
For a prospective investor, the weakest pillars are the two that measure whether the business generates value and whether informed capital is building positions. The cash engine pillar reflects a negative return on invested capital and a 0% free cash flow yield, meaning the reported financials do not currently show a self-funding operation. The flow pillars indicate little evidence of supportive institutional or insider conviction in the source data. The balance-sheet pillar is middling rather than distressed: the Altman Z-Score of 2.5 and Debt/Equity of 0.5 sit in the range the rating treats as neutral, but a Piotroski F-Score of 3 out of 9 points to weak financial-quality signals. Beta of 1.0 places macro sensitivity at market-average, so the rating's macro pillar does not add a directional penalty beyond sector exposure.
Upside drivers implied by the data would have to come from a turnaround in operating performance, which the reported trend does not yet show. Valuation tradeoffs are difficult to assess because P/E, forward P/E, EV/EBITDA, and EPS are not available in source data; the shares trade at a $11.1M market capitalization against negative operating and net margins. The 52-week range of $1.92 - $68.85 is extremely wide and should be weighed as evidence of volatility rather than as a valuation anchor.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $1.0M | $-14.7M | $-13.8M | N/A | $-13.8M | N/A | N/A |
| FY 2024 | $1.7M | $-13.3M | $-11.7M | N/A | $-10.3M | N/A | N/A |
| FY 2023 | $0.8M | $-11.1M | $-9.6M | N/A | $-7.6M | N/A | N/A |
Per the SEC financials, reported revenue moved from $0.8M (FY 2023) to $1.7M (FY 2024) before declining to $1.0M (FY 2025), while operating losses widened each year, reaching $-14.7M in FY 2025. Per the market data section, ROIC is -35% and FCF yield is 0%. The Roarable RQD rating reports an Altman Z-Score of 2.5, a Piotroski F-Score of 3 out of 9, and a Debt/Equity ratio of 0.5. Cash and debt balances are not available in source data for any period.
Per the recent news and catalysts section, the most recent headline reports an Astrotech proposal to provide lunar power infrastructure under a NASA program, flagged YELLOW. A second headline states that at least $20M in sale value is needed for first bonuses under a new plan, flagged YELLOW. A Form 4 filing by director Tom Wilkinson is listed, flagged YELLOW. A "Risk Watch" item titled "Discipline and Rules-Based Execution in ASTC Response" is flagged RED. A price-action item reports the stock slipping 1.92% to $5.10, and a Manila Times item references an appointment of a Chief Financial Officer at Innventure, a separate entity, which the source does not connect to ASTC operationally. The proprietary signals list in the Butterfly graph is empty.
Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. Upstream suppliers, downstream customers, and sector correlations are therefore not available in source data. The only sector-level context provided is the Health Care sector and Biotechnology: Laboratory Analytical Instruments industry classification. A prospective investor should watch whether the NASA-related lunar infrastructure proposal translates into revenue, since the source does not establish any link between that activity and the reported health-care industry classification.
Real-time company headlines, analyst actions, and sector developments for Astrotech Corporation (ASTC) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Astrotech Corporation (ASTC) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Astrotech Corporation (ASTC) market action, institutional positioning, and fundamental catalysts.
Investing.com Nigeria report covering Astrotech Corporation (ASTC) market action, institutional positioning, and fundamental catalysts.
Stock Traders Daily report covering Astrotech Corporation (ASTC) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Astrotech Corporation (ASTC) market action, institutional positioning, and fundamental catalysts.
The Manila Times report covering Astrotech Corporation (ASTC) market action, institutional positioning, and fundamental catalysts.
The proposed project, Astrotech Vertical Solar Array Maturation (AVSAM), would advance critical elements of the Astrotech Mobile Power System (AMPS) for potential future lunar surface use.The proposal targets maturation
Gainers Republic Power Group (NASDAQ:RPGL) stock moved upwards by 55.5% to $24.09 during Thursday's regular session. The company's market cap stands at $44.9 million. Alpha Modus Holdings (NASDAQ:AMOD) shares
Welcome to the ASTC (Astrotech Corporation) Roar Pit. Current RQD Composite is 28/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Laboratory Analytical Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on ASTC, but look at what you are paying: current EV/EBITDA multiples with 47.5% gross margins. Unless Astrotech Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on ASTC, the market is fixating on short-term headline noise in Biotechnology: Laboratory Analytical Instruments and ignoring the balance sheet and cash flow trajectory. At $5.25 (52-wk range $1.92 - $68.85), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).